Stimit AG

Executive Summary

Stimit AG is a Swiss medical device company developing a non-invasive diaphragm stimulation technology to prevent diaphragm atrophy in mechanically ventilated ICU patients. Founded in 2016 and headquartered in Zug, the company addresses a critical unmet need: prolonged ventilation leads to respiratory muscle weakness, increasing morbidity and healthcare costs. Stimit's device aims to reactivate natural breathing by delivering targeted electrical stimulation through the skin, potentially reducing ventilation duration and complications. Currently in pre-clinical stage, the company has not disclosed funding or valuation but operates in a large addressable market of over 1 million mechanically ventilated patients annually in the US and Europe. If successful, Stimit’s technology could become a standard of care in ICUs, offering a non-pharmacological approach to preserve respiratory function. Key risks include regulatory hurdles, clinical validation, and competition from established respiratory device manufacturers.

Upcoming Catalysts (preview)

• TBDFirst-in-human clinical trial initiation40% success
• TBDCE Mark certification pathway announcement35% success
• TBDStrategic partnership or grant funding for clinical development50% success